• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services


  • Print
  • Share
  • E-mail

Combivir (lamivudine plus zidovudine)

Audience: Pharmacists, distributors, and healthcare professionals

GlaxoSmithKline announced that the company received four reports of suspect bottles containing 60 tablets of Combivir (lamivudine plus zidovudine) that actually contained another medicine, Ziagen (abacavir sulfate) Tablets. The company has determined that counterfeit labels for Combivir Tablets were placed on two bottles of Ziagen and labels on another two bottles are suspect. Both medicines are used as part of combination regimens to treat HIV infection. The incidents appear to be isolated and limited in scope. No injuries or adverse reactions have been reported. Company tests have shown no problems with the medicine itself.

[May 14, 2002 Letter to Healthcare Professionals - GlaxoSmithKline] 
[May 14, 2002 Letter to Pharmacists - GlaxoSmithKline] 
[May 10, 2002 Press Release - GlaxoSmithKline]